Double-Punch combo trial aims to keep advanced lung cancer at bay

This study tested if adding a precise, high-dose radiation treatment (SBRT) to an immunotherapy drug (durvalumab) could better control stage 3 lung cancer after patients finished standard chemotherapy and radiation. The goal was to see if damaging the tumor with SBRT makes the immune-stimulating drug more effective at fighting remaining cancer cells. Researchers measured how safe the combination was and how long patients lived without their cancer getting worse.